Early-stage potential Iaterion is a small biotech startup focused on antiviral and immune-modulating therapeutics with ambitions to advance AVIM1 to Phase 1 trials. This presents an opportunity to engage early with a company that may seek outsourced R&D support, preclinical services, and regulatory consulting as it accelerates its program.

COVID-19 focus The company is actively addressing COVID-19 and coronaviruses, including antiviral compounds and immune-modulating strategies. This signals a potential fit for pandemic preparedness collaborations, antiviral assays, clinical trial design input, and access to niche antiviral discovery services.

High potency leads Lead compounds are described as 50-100 times more potent than Remdesivir, indicating strong scientific promise. This creates a sales angle for partnering on translational research, toxicology support, biomarker development, and GMP-ready manufacturing discussions as they scale.

Funding-ready traction Revenue is modest but suggests ongoing development funding. This profile may attract investors or grant programs and presents an avenue for professional services in grant writing support, strategic consulting, and funded collaboration frameworks that help extend runway.

Lean operations With a small team (2-10 employees), Iaterion likely relies on external collaborations and CROs for extensive research tasks. This opens opportunities to offer end-to-end CRO partnerships, accelerated project management, and flexible resourcing proposals to scale their programs efficiently.